Business Context and Reporting Period
This Form 8-K was filed by Capricor Therapeutics, Inc. on March 5, 2015. The report details a corporate event regarding the listing status of the company's common stock.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a listing event and does not contain financial statements or performance metrics.
Material Changes
The primary material change is the approval by The Nasdaq Stock Market LLC to list Capricor Therapeutics' common stock on the NASDAQ Capital Market. The stock is expected to begin trading under the symbol "CAPR" on Monday, March 9, 2015. Until the market closes on Friday, March 6, 2015, the stock will continue to trade on the OTCQB under the same symbol.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies beyond the transition of the trading venue.
Investor Verification Checklist
- Confirm the commencement of trading on the NASDAQ Capital Market on March 9, 2015.
- Verify the cessation of OTCQB trading on March 6, 2015.
- Review the attached press release (Exhibit 99.1) for additional details on the listing approval.